OKYO Pharma: Targeting the $5 Billion Dry Eye Disease Market
Sep. 7, 2022
OKYO Pharma (NASDAQ: OKYO) is a bio-pharmaceutical company focused on the discovery & development of first-in-class pharmaceutical therapies to treat inflammatory eye diseases including dry eye and ocular pain. OKYO is developing a lipidated chemerin-peptide drug candidate OK-101, designed to target a key ocular receptor controlling inflammation and ocular pain. The drug, developed by a unique proprietary membrane anchored technology, is designed to increase agonist potency and ocular residence time. Visit OKYOinfo.com to learn more.
